MAITHRI DRUGS PRIVATE LTD

Overview

MAITHRI DRUGS PRIVATE LTD is an active pharmaceutical ingredient (API) supplier with 93 active FDA Type II Drug Master Files, covering ABROCITINIB; ADAPALENE USP; ALBENDAZOLE USP; APREPITANT USP; AVACOPAN; BESIFLOXACIN HYDROCHLORIDE.

API / Drug Master Files

MAITHRI DRUGS PRIVATE LTD holds 93 active (93 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• PREGABALIN USPActive2026-03-18
• LITHIUM CITRATE USPActive2026-03-02
• LITHIUM CARBONATE USPActive2026-03-02
• BUPROPION HYDROCHLORIDE USPActive2026-01-30
• SODIUM BICARBONATE USPActive2025-12-31
• CENOBAMATEActive2025-11-04
• IVACAFTORActive2025-11-01
• MONOBASIC POTASSIUM PHOSPHATE USPActive2025-10-29
• MARIBAVIRActive2025-09-30
• DIBASIC POTASSIUM PHOSPHATE USPActive2025-09-30
• POTASSIUM ACETATE USPActive2025-09-02
• DARIDOREXANT HYDROCHLORIDEActive2025-07-31
• NICARDIPINE HYDROCHLORIDE USPActive2025-07-16
• MAGNESIUM SULFATE DRIED USPActive2025-06-30
• XANOMELINE TARTRATEActive2025-05-31

Showing 15 of 93 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to MAITHRI DRUGS PRIVATE LTD in our records. PharmaTek screens the full directory against live FDA enforcement data.